Name: Sotyktu (deucravacitinib)
Brand: Bristol Myers Squibb

Sotyktu is an oral, once-daily medicine that inhibits tyrosine kinase 2 through allosteric binding at the JH2 pseudokinase domain, reducing signaling downstream of IL-23, IL-12, and type I interferons. It was the first selective TYK2 inhibitor approved by the U.S. FDA, receiving initial approval for moderate to severe plaque psoriasis in 2022.

The brand site, operated by Bristol Myers Squibb, lists active psoriatic arthritis alongside plaque psoriasis as its approved indications. As the reference approved oral allosteric TYK2 inhibitor, it anchors the selective TYK2 inhibitor class in autoimmune dermatology and rheumatology.

Sotyktu (deucravacitinib) - Direct Competitors

Attribute	Sotyktu (deucravacitinib)	ARTS-011 (TYK2 allosteric inhibitor)	Envudeucitinib (ESK-001)	Fadeucravacitinib (ICP-488)	Zasocitinib (TAK-279)
Provider	Bristol Myers Squibb bms.com10.6B raised · Public	Allorion Therapeutics alloriontx.com90M raised · Series B	Alumis alumis.com270M raised · Series B	InnoCare Pharma innocarepharma.com	Takeda takeda.com57.8M raised · Series B
Founded	1887	2020	2021	2015	1781
Sells To	Consumers, Enterprise	Enterprise	Enterprise	—	Enterprise
Pricing Model	Recurring, Software	Recurring, Software	Recurring, Software	—	—
Ownership	Public	Private	Equity, Venture Capital	—	Venture Capital